In The News

July 13, 2016

TARIS Biomedical® Initiates Phase 1b Clinical Trial of TAR-200 (GemRIS™) in Patients with Muscle-Invasive Bladder Cancer

Deshpande spinout, TARIS Biomedical LLC, announced the initiation of a Phase 1b clinical trial of TAR-200 (GemRIS™) in patients with muscle-invasive bladder cancer (MIBC).

Read more
June 1, 2016

Slippery Times Ahead For Sticky Problems

Deshpande grantee, Kripa Varanasi, and his team are looking at new and creative ways to use their LiquiGlide coating.

Read more
May 5, 2016

1366 Technologies Receives $10 Million Investment from Hanwha Investment Corporation

Deshpande spinout, 1366 Technologies will use the $10 million investment from the Hanwha Investment Corporation toward the construction of 1366’s first large-scale commercial factory, scheduled to be online in 2017.

Read more
April 14, 2016

Implantable device targets pancreatic cancer

Deshpande grantees and MGH have now developed a small, implantable device that delivers chemotherapy drugs directly to pancreatic tumors.

Read more

Pages